Reprogramming Inflammation at Its Source
Noa Therapeutics is on a mission to change the lives of patients living with chronic inflammatory diseases.
At the forefront of precision-designed small molecules, Noa is transforming immunology, offering patients lasting remission, greater ease, and better real-world results
Breaking Free from Convention
For millions living with chronic inflammatory diseases, current therapies only offer temporary relief or limited efficacy. At Noa Therapeutics, we are at the forefront of disease modifying therapies for inflammatory diseases to address one of the most fundamental challenges in immunology: unlocking the aryl hydrocarbon receptor (AhR), a master regulator of immune and barrier homeostasis.
Noa Therapeutics is selectively modulating AhR signalling pathways through biased signal induction to deliver safe and effective novel therapeutics and unlock AhR’s platform potential.
Our Approach
Our platform is built on precision targeting of AhR’s non-canonical signaling, enabling control of immune pathways with unprecedented specificity. By tuning upstream disease-relevant transcriptional pathways, rather than suppressing the immune system, we circumnavigate immune redundancies to resolve inflammation at its source, delivering therapies with superior efficacy, safety, and patient impact.
With a scalable platform leveraging parallelized high throughput screening approaches, Noa is rapidly advancing numerous assets in dermatology and gastrointestinal diseases, and is positioned at a critical inflection point, ready to lead the next generation of I&I therapies.
The impact of Inflammatory barrier diseases
Adults
Children
Persons affected by Atopic Dermatitis in the United States
%
of patients are non-responsive to adaptive immune therapies
Patients dissatisfied with current treatment options
Our Research
AhR is a master transcriptional regulator at the interface of immunity, metabolism, and epithelial barrier function. However, AhR is context dependent. Ligand and cell specific “bias” is the key to programmable therapeutic potential. Our discovery engine combines parallelized high-throughput screening, structure-guided chemistry, and biomarker-driven design to deliver proprietary novel therapeutics to precisely activate only the therapeutic AhR pathways, without engagement of deleterious pathways. Through non-canonical AhR signaling our platform enable:
Immune Modulation
Modulate innate and adaptive immunity to stop pathological inflammation while maintaining essential host defenses
Barrier Restoration
Drive expression of protective proteins to strengthen the cellular barriers, reducing pathogen penetration and allergen sensitization
Microbiome Modulation
Address root causes, not just symptoms, by resetting immune tolerance and barrier homeostasis through upstream transcriptional intervention to reverse disease progression
We design medicines around what patients tell us they need: durability, safety, simplicity, and dignity. We commit to plain language science communication, inclusive trial design, and real-world evidence that reflects lived experience.
Our unique AhR approach is designed to deliver dual benefits; immune modulation and barrier restoration, while prioritizing safety, making it a potential long-term solution for both adult and pediatric populations.
Our Program
Our discovery engine screens non-canonical biased AhR ligands, fine-tuned to crosstalk with transcriptional pathways such as STAT1/3, NF κB (RelB), and ERα/AR for the safe and selective control of innate and adaptive immunity, barrier integrity, and metabolic inflammation.
We integrate RNA seq, in silico enrichment, and translational biomarkers to advance quickly and rigorously from preclinical signal to clinical proof of concept.
Noa Therapeutics’ proprietary small molecules are advancing across several high value indications:
1) Noa Therapeutics’ development candidate, NOA-104 is advancing through IND enabling studies. Preclinical proof of concept studies demonstrates best-in-class efficacy with game changing weekly administration potential for atopic dermatitis.
2) Proprietary NCEs are advancing with early in vitro proof of concept as an oral for high value gastrointestinal indications.
Team
Our team brings together drug discovery leaders, immunology experts, and biotech veterans who share a patient-first mindset and a relentless focus on precision science. We are united by a vision to create therapies that redefine the future of immune health.
Carla Spina
CEO & Co-FounderFounding Director. Seasoned innovator. Over 18 years experience in skin and wound device and drugs. Leading discovery through clinical phase study and commercialization.
in
Serena Mandla P.Eng, MASc
CSO & Co-FounderExperienced innovator in the development, manufacturing, and commercialization of novel small peptides for cardiovascular and skin disease applications.
in
